UCB SA (OTCMKTS:UCBJY) Short Interest Up 859.4% in April

UCB SA (OTCMKTS:UCBJY - Get Free Report) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 30,700 shares, a growth of 859.4% from the March 31st total of 3,200 shares. Based on an average daily volume of 133,100 shares, the short-interest ratio is currently 0.2 days. Currently, 0.0% of the shares of the stock are sold short.

UCB Trading Up 0.1 %

OTCMKTS:UCBJY traded up $0.10 on Thursday, reaching $91.91. The stock had a trading volume of 25,896 shares, compared to its average volume of 43,632. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. UCB has a 1-year low of $63.58 and a 1-year high of $106.60. The stock has a fifty day moving average price of $89.64 and a 200-day moving average price of $94.13.

UCB Increases Dividend

The firm also recently disclosed a dividend, which will be paid on Wednesday, May 14th. Shareholders of record on Tuesday, April 29th will be paid a $0.4838 dividend. The ex-dividend date is Monday, April 28th. This represents a yield of 0.62%. This is a positive change from UCB's previous dividend of $0.46.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.